德展健康：聘任高涛为公司董事会秘书

Company Governance - The company announced the appointment of Mr. Gao Tao as the Secretary of the Board and Ms. Wu Ling as the Chief Financial Officer, enhancing its governance structure [1] - The appointments were approved by the Board of Directors following nominations from the Chairman and the Co-Chairman [1] Financial Performance - For the first half of 2025, the company's revenue composition is as follows: 99.0% from the pharmaceutical industry, 0.63% from peptides, and 0.37% from other sources [1] - The current market capitalization of the company is 8.1 billion yuan [2]